Abstract
The theranostic combination of 68Ga-labeled diagnostic agents with 90Y- or 177Lu-labeled therapeutic somatostatin ligands has been shown to be a remarkably accurate and effective way to characterize and treat neuroendocrine tumors. Food and Drug Administration approval of such agents is expected to
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
